A cryptogenic stroke is an ischemic stroke with no identifiable cause after standard testing. Despite brain imaging confirming that a stroke occurred, doctors cannot pinpoint why. This accounts for a significant portion of all ischemic strokes, and it leaves patients in a frustrating gray area: something clearly went wrong, but the usual suspects (a blocked artery, a known heart rhythm problem, disease in the brain’s small blood vessels) don’t explain it.
Why Some Strokes Have No Clear Cause
Every ischemic stroke happens because a blood clot blocks blood flow to part of the brain. In most cases, doctors can trace that clot back to one of a few well-known sources: fatty plaque buildup in a major artery, a heart rhythm disorder like atrial fibrillation that lets blood pool and clot, or disease in the brain’s tiny blood vessels. When none of these explanations fit after a thorough workup, the stroke is classified as cryptogenic.
That doesn’t mean there’s no cause. It means the cause is hidden. In many cases, deeper or longer testing eventually reveals what happened. The label “cryptogenic” is really a starting point for further investigation, not a final answer.
Hidden Causes That Often Surface Later
Three culprits account for a large share of strokes initially labeled cryptogenic.
Undetected Atrial Fibrillation
Atrial fibrillation, an irregular heart rhythm that raises stroke risk dramatically, can come and go unpredictably. A standard 24-hour heart monitor catches only a snapshot. When doctors implant a small monitoring device under the skin and watch for months or years, the picture changes. In a study of 840 cryptogenic stroke patients followed with these implantable monitors, about 33% were found to have atrial fibrillation within three years. That’s a striking number: roughly one in three patients whose stroke had no explanation turned out to have a heart rhythm problem that simply hadn’t been caught yet.
Patent Foramen Ovale (PFO)
Before birth, everyone has a small opening between the two upper chambers of the heart. It normally closes shortly after birth, but in about 25% of adults, it doesn’t seal completely. This leftover gap, called a patent foramen ovale, can allow a blood clot from the veins to cross into the arteries and travel to the brain. Roughly one in four people have a PFO and never have a problem, so finding one after a stroke doesn’t automatically mean it caused the stroke. A scoring system called the RoPE score helps estimate whether a PFO is the likely culprit or just a coincidence. It weighs factors like age and the absence of traditional stroke risk factors such as high blood pressure, high cholesterol, and diabetes. Younger patients without those risk factors are more likely to have a stroke directly caused by a PFO.
In patients with a RoPE score of 7 or higher, closing the PFO with a small device threaded through a vein reduced the risk of another stroke by about 69% compared to medication alone. In patients with lower scores, the benefit was much smaller and not statistically significant. This is why PFO closure isn’t offered to everyone who has one. It matters most when the PFO is likely the actual cause, not a bystander.
Aortic Arch Plaques
Fatty deposits in the aorta, the body’s largest artery, can also send clots to the brain. These plaques are especially dangerous when they have irregular surfaces or loose material attached. Among cryptogenic stroke patients, having large or complex plaques in the aortic arch increased the risk of another stroke or death by six to nine times compared to patients without them. The risk was seen almost exclusively in cryptogenic stroke patients, suggesting these plaques played a direct role when no other cause was found. Standard testing doesn’t always look closely at the aortic arch, which is one reason these plaques go undetected.
How Doctors Investigate a Cryptogenic Stroke
The initial workup after any stroke includes brain imaging (CT or MRI), blood vessel imaging, basic blood tests, and at least 24 hours of heart rhythm monitoring. When that standard evaluation comes back without a clear answer, the investigation expands.
Transesophageal echocardiography, where a small ultrasound probe is passed down the throat to get a close view of the heart, is considered the gold standard for evaluating cryptogenic stroke. It can detect PFOs, blood clots in the heart, and aortic plaques that a standard chest ultrasound would miss. A CT scan of the heart and aorta can add complementary information. Studies have shown that using both techniques together catches more embolic sources than either one alone.
For heart rhythm monitoring, the jump from 24 hours to weeks or months makes an enormous difference. Outpatient telemetry worn for a few weeks catches more atrial fibrillation than a standard hospital monitor. For the highest detection rate, implantable cardiac monitors that continuously record heart rhythm for up to three years are used. These small devices sit just under the skin of the chest and automatically flag irregular rhythms.
Advanced vascular imaging can also help. High-resolution MRI can characterize plaques inside blood vessels, distinguishing dangerous unstable plaques from stable ones. Transcranial Doppler monitoring can detect tiny clot fragments (microemboli) traveling through brain arteries in real time, pointing toward an active embolic source. Bubble studies, where agitated saline is injected into a vein during ultrasound, can reveal a PFO or other abnormal connections between the venous and arterial circulation.
Embolic Stroke of Undetermined Source (ESUS)
In 2014, researchers proposed a more specific term for a subset of cryptogenic strokes: embolic stroke of undetermined source, or ESUS. This category applies when the stroke pattern on imaging looks like it was caused by a clot that traveled from somewhere else (an embolism), but the source can’t be found. To qualify as ESUS, a stroke must meet four criteria: the brain infarct isn’t a small, deep “lacunar” type (which results from small vessel disease); there’s no significant narrowing in the arteries feeding the affected brain area; there’s no major heart condition known to produce clots; and no other specific cause like an artery tear or blood vessel inflammation has been identified. A minimum of 24 hours of heart rhythm monitoring with automated detection is also required.
The ESUS concept was designed partly to guide treatment research. The thinking was that if these strokes are caused by embolism, blood thinners (anticoagulants) might prevent recurrence better than antiplatelet drugs like aspirin. Clinical trials testing this hypothesis, however, did not show a clear benefit of anticoagulation for the broad ESUS population, likely because the category still lumps together patients with very different underlying mechanisms.
Risk of Another Stroke
Recurrence risk after a cryptogenic stroke sits in a middle range: higher than strokes caused by small vessel disease, but lower in the short term than strokes from large artery blockages. In the first three months, about 4% to 6% of patients have another stroke. By two years, the recurrence rate climbs to roughly 14% to 20%. At five years, a study in Olmsted County, Minnesota found a 33% recurrence rate, which was not significantly different from strokes with known causes.
Certain findings raise the risk further. Patients with aortic arch plaques had recurrence rates comparable to the highest-risk stroke subtypes. Those with undetected atrial fibrillation found later through monitoring are at elevated risk until that rhythm problem is treated. This is why the extended investigation matters: identifying the hidden cause directly changes the prevention strategy and can substantially lower the chance of a second stroke.
How Cryptogenic Strokes Are Managed
Treatment depends heavily on what, if anything, the extended evaluation uncovers. If atrial fibrillation is eventually detected, the treatment shifts to anticoagulation, which is far more effective at preventing clots from the heart than antiplatelet therapy alone. If a PFO is found and scored as likely causative, closure of the opening with a catheter-delivered device is an option, particularly for patients 60 and younger.
When no hidden cause is found despite thorough testing, antiplatelet therapy remains the standard approach. Aggressive management of vascular risk factors (blood pressure, cholesterol, blood sugar, smoking) is critical regardless of the stroke subtype. For patients with aortic arch plaques, identifying and treating those risk factors is especially important given the elevated recurrence risk those plaques carry.
Long-term monitoring plays a dual role: it both searches for the underlying cause and watches for recurrence. Many patients with cryptogenic stroke will have an implantable cardiac monitor placed during the initial evaluation period, and they may carry it for years. Each new finding has the potential to reclassify the stroke and refine the prevention plan.